Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating chronic spontaneous urticaria or CSU in adults and adolescents aged 12 years and older.
The recommendation applies to patients with moderate-to-severe disease who have an inadequate response to histamine-1 antihistamines (H1AH) and are naive to anti-immunoglobulin E (IgE) therapy. A final decision is expected in the coming months.
Dupixent is approved for chronic spontaneous urticaria in certain adults and adolescents in several countries including Japan and the United States. Chronic spontaneous urticaria is a chronic, inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.